Inhaled nitrite therapy for pulmonary hypertension in connective tissue diseases
- Conditions
- Pulmonary artery hypertension in systemic sclerosis patientsSystemic sclerosisPulmonary artery hypertensionInhaled nitriteMean pulmonary artery pressure
- Registration Number
- TCTR20230517002
- Lead Sponsor
- Mahidol University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending (Not yet recruiting)
- Sex
- All
- Target Recruitment
- 23
1.Systemic sclerosis patients with and without interstitial lung disease.
2.Patients in clinically stable state
3.Do not receive medication which affect platelet function (NSAIDs or anti-platelet drugs) within 2 weeks.
4.Patients who were nonsmokers, not drinking alcohol and not addicting illegal drugs.
1.The use of organic nitrate and pulmonary vasodilator agents (calcium channel blockers or endothelin receptor antagonists) other than sildenafil.
2.Patients with systolic blood pressure lower than 100 mmHg and/or diastolic blood pressure lower than 70 mmHg
3.Patients with hematocrit lower than 24%
4. Patients with methemoglobin greater than 1%
5.Patients who taking antiplatelet medications.
6.Patients who smoking, drinking alcohols and being a drug addiction.
7. Patients with glomerular filtration rate lower than 60 mL/min/1.73 m2
8.Patients with severe co-morbidities (heart failure, ischemic heart diseases, COPD, diabetes mellitus, thyroid disease, chronic kidney disease)
9.Pregnant patients
10.Patient who denied or withdrawn from the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Mean pulmonary artery pressure Every 1 min during intrite inhalation Right heart catheterization
- Secondary Outcome Measures
Name Time Method Pulmonary vascular resistance Every 1 min during intrite inhalation Right heart catheterization